公开(公告)号：WO2019094482A1

公开(公告)日：2019-05-16

申请号：PCT/US2018/059645

申请日：2018-11-07

申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： HO, Mitchell ,  LI, Nan ,  LI, Dan

IPC分类号： C07K14/725 ,  C07K14/71

CPC分类号： C07K14/7051 ,  C07K14/71

摘要： Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen- specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin- specific monoclonal antibody, fused to a CD8α hinge region, a CD8α transmembrane region, a 4-1BB co- stimulatory domain and a CD3ζ signaling domain. Isolated host cells, such as isolated T cells that co- express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

公开(公告)号：WO2019084053A1

公开(公告)日：2019-05-02

申请号：PCT/US2018/057168

申请日：2018-10-23

申请人： MAGENTA THERAPEUTICS, INC.

发明人： PEARSE, Bradley R. ,  COOKE, Michael ,  BOITANO, Anthony ,  PALCHAUDHURI, Rahul ,  MCDONOUGH, Sean ,  PANWAR, Rajiv ,  GLANVILLE, Jacob

IPC分类号： A61K39/395 ,  C07K14/435 ,  C07K16/28

CPC分类号： C07K14/71 ,  C07K16/2803 ,  C07K2317/92 ,  C07K2317/94

摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, and antigen-binding fragments thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

公开(公告)号：WO2019070856A1

公开(公告)日：2019-04-11

申请号：PCT/US2018/054164

申请日：2018-10-03

申请人： PRECISION BIOSCIENCES, INC.

发明人： JANTZ, Derek ,  SMITH, James, Jefferson ,  MACLEOD, Daniel, T.

IPC分类号： C07K14/71 ,  C12N5/00

CPC分类号： C07K14/71 ,  C12N5/0087

摘要： The present disclosure provides modified EGFR peptides useful in genetically-modified cells to allow for selection and enrichment of those cells expressing the modified EGFR peptide. For example, isolation of genetically-modified cells expressing a modified EGFR peptide can allow for selection of cells that co-express a chimeric antigen receptor or exogenous T cell receptor. In those instances wherein the genetically-modified cells present adverse effects when administered to a subject, the modified EGFR finds further use as a suicide gene upon administration of an anti-EGFR antibody, leading to depletion of the genetically-modified cells. Also disclosed herein are plasmids and viral vectors comprising a nucleic acid sequence encoding the modified EGFR peptides, and methods of administering compositions comprising the modified EGFR peptides to subjects in order to reduce the symptoms, progression, or occurrence of disease, such as cancer.

公开(公告)号：WO2019055902A1

公开(公告)日：2019-03-21

申请号：PCT/US2018/051311

申请日：2018-09-17

申请人： AMGEN INC.

发明人： WEXLER-COHEN, Yael ,  FESINMEYER, Robert Matthew ,  GOSS, Monica Michelle ,  KANAPURAM, Sekhar ,  KAUSHIK, Rahul Rajan ,  PADALA, Sai Chakradhar

IPC分类号： A61K9/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K38/17 ,  C07K14/71

CPC分类号： A61K9/0019 ,  A61K38/179 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  C07K14/71

摘要： VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEGFR-Fc fusion protein is aflibercept.

公开(公告)号：WO2019018632A1

公开(公告)日：2019-01-24

申请号：PCT/US2018/042873

申请日：2018-07-19

申请人： MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

发明人： LI, Zihai

IPC分类号： C07K7/06 ,  C07K7/08 ,  C07K14/705 ,  A61K38/00

CPC分类号： C07K14/71 ,  A61K31/397 ,  A61K38/58 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2818 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  A61K2300/00

摘要： Provided herein are methods of inhibiting GARP cleavage, such as by administering a GARP peptide or a direct thrombin inhibitor. Further provided herein are methods of treating cancer by inhibiting GARP cleavage as well as methods of identifying subjects with platelet activation who would benefit from inhibition of GARP cleavage.

公开(公告)号：WO2019010201A1

公开(公告)日：2019-01-10

申请号：PCT/US2018/040751

申请日：2018-07-03

申请人： YALE UNIVERSITY

发明人： SPIEGEL, David ,  COLLINS, Jesse ,  MUTHUSAMY, Viswanathan

IPC分类号： C12N5/0783 ,  C12N5/10 ,  C12N15/12 ,  C12N15/63 ,  C07K14/725 ,  A61K35/17 ,  A61K47/66 ,  C07D249/04 ,  C07D473/18 ,  A61K31/4192 ,  A61K31/522 ,  A61P35/00 ,  A61P13/08

CPC分类号： C07D249/04 ,  A61K35/17 ,  A61K45/06 ,  A61K47/555 ,  A61P13/08 ,  A61P35/00 ,  C07D401/12 ,  C07D473/18 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/71 ,  C07K2319/03 ,  C12N5/0638 ,  C12N2510/00

摘要： In one embodiment, the invention' provides a chimeric antigen receptor (CAR) T cell which is conjugated to a bi-functional molecule which is specific for both an extracellular binding domain of the chimeric antigen receptor (CAR) T cell and prostate-specific membrane antigen (PSMA). The chimeric antigen receptor (CAR) T cell contains a T cell signaling domain and the extracellular binding domain of the chimeric antigen receptor (CAR) T cell is not specific for prostate-specific membrane antigen (PSMA). Compositions and methods of treatment using these CAR T cells are also disclosed.

公开(公告)号：WO2018229215A1

公开(公告)日：2018-12-20

申请号：PCT/EP2018/065857

申请日：2018-06-14

申请人： CAMBRIDGE ENTERPRISE LIMITED

发明人： HYVÖNEN, Marko ,  WANG, Xuelu ,  DONALDSON, Jane

IPC分类号： C07K14/71

CPC分类号： C07K14/71

摘要： This invention relates to follistatin-resistant variants of activin that are modified to include mutations at residues Asp27 and Gln98. These activin variants are shown to display increased resistance to follistatin inhibition relative to wild-type activin and hence increased signaling potency in cell culture. Modified activin and methods for its production and use are provided.

公开(公告)号：WO2017146979A1

公开(公告)日：2017-08-31

申请号：PCT/US2017/018085

申请日：2017-02-16

申请人： ELI LILLY AND COMPANY ,  AMUNIX OPERATING INC.

发明人： BALDWIN, David Bruce ,  BEALS, John Michael ,  KORYTKO, Andrew Ihor ,  MCLAUGHLIN, Bryant Rhodius ,  SCHELLENBERGER, Volker

IPC分类号： A61K38/28 ,  A61P3/10

CPC分类号： C07K14/72 ,  A61K38/179 ,  A61K38/1796 ,  A61K38/28 ,  A61K47/64 ,  C07K14/62 ,  C07K14/71 ,  C07K2319/31

摘要： The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound.

摘要翻译： 本发明涉及该领域内的医学领域和治疗糖尿病或高血糖症。 更具体地说，本发明涉及降低血糖的化合物，含有这种化合物的药物组合物，以及这种化合物的治疗用途。

公开(公告)号：WO2017085691A1

公开(公告)日：2017-05-26

申请号：PCT/IB2016/056980

申请日：2016-11-18

申请人： ADVAXIS, INC.

发明人： EAPEN, Anil ,  PETIT, Robert

IPC分类号： C12N15/74 ,  C07K14/195 ,  C07K14/705 ,  C07K14/71 ,  A61K38/16 ,  A61K38/17 ,  B01D61/14 ,  G01N21/59

CPC分类号： A61K38/16 ,  A61K38/17 ,  B01D61/18 ,  B01D61/22 ,  B01D65/08 ,  B01D2311/14 ,  B01D2311/16 ,  B01D2311/25 ,  B01D2313/50 ,  B01D2315/10 ,  B01D2315/16 ,  B01D2321/40 ,  C07K14/195 ,  C07K14/71 ,  C07K2319/00 ,  C12N9/12 ,  C12N9/6445 ,  C12Y207/10001 ,  G01N21/59

摘要： Provided herein are an apparatus and process for manufacturing a formulation comprising a drug substance, said drug substance comprising a recombinant Listeria strain comprising a prostate specific antigen (PSA) or a chimeric HER2 antigen fused to a Listeriolysin O (LLO) protein fragment.

摘要翻译： 本文提供了用于制造包含药物的制剂的设备和方法，所述药物包含含有前列腺特异性抗原（PSA）或嵌合体的重组利斯特氏菌属菌株 HER2抗原与Listeriolysin O（LLO）蛋白片段融合。

公开(公告)号：WO2017019454A2

公开(公告)日：2017-02-02

申请号：PCT/US2016/043376

申请日：2016-07-21

申请人： MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

发明人： BOGATKEVICH, Galina S. ,  SHIRAI, Yuichiro ,  SILVER, Richard, M.

IPC分类号： A61K38/17 ,  C07K14/705

CPC分类号： C07K14/705 ,  A61K38/00 ,  A61K45/06 ,  C07K14/71

摘要： The invention provides anti-fibrotic peptides derived from the C- terminal region of the MET receptor tyrosine kinase. Polynucleotides encoding these peptides, host cells transformed with the polynucleotides, and methods of using these peptides and polynucleotides are included in the invention. Uses of these peptides, polynucleotides and expression vectors include the treatment of fibrosis in a subject.

摘要翻译： 本发明提供衍生自MET受体酪氨酸激酶的C-末端区域的抗纤维化肽。 编码这些肽的多核苷酸，用多核苷酸转化的宿主细胞，以及使用这些肽和多核苷酸的方法包括在本发明中。 这些肽，多核苷酸和表达载体的用途包括在受试者中治疗纤维化。